Abstract:Alzheimer's disease (AD) is currently constrained by limited clinical treatment options. The initial pathophysiological event, which can be traced back to decades before the clinical symptoms become apparent, involves the excessive accumulation of amyloid-beta (Aβ), a peptide comprised of 40–42 amino acids, in extraneuronal plaques within the brain. Biochemical and histological studies have shown that overaccumulation of Aβ instigates an aberrant escalation in the phosphorylation and secretion of tau, a microtubule-binding axonal protein. The accumulation of hyperphosphorylated tau into intraneuronal neurofibrillary tangles is in turn correlated with microglial dysfunction and reactive astrocytosis, culminating in synaptic dysfunction and neurodegeneration. As neurodegeneration progresses, it gives rise to mild clinical symptoms of AD, which may eventually evolve into overt dementia. Synaptic loss in AD may develop even before tau alteration and in response to possible elevations in soluble oligomeric forms of Aβ associated with early AD. These findings largely rely on post-mortem autopsy examinations, which typically involve a limited number of patients. Over the past decade, a range of fluid biomarkers such as neurogranin, α-synuclein, visinin-like protein 1 (VILIP-1), neuronal pentraxin 2, and β-synuclein, along with positron emission tomography (PET) markers like synaptic vesicle glycoprotein 2A, have been developed. These advancements have facilitated the exploration of how synaptic markers in AD patients correlate with cognitive impairment. However, fluid biomarkers indicating synaptic loss have only been validated in cerebrospinal fluid (CSF), not in plasma, with the exception of VILIP-1. The most promising PET radiotracer, [ 11 C]UCB-J, currently faces significant challenges hindering its widespread clinical use, primarily due to the necessity of a cyclotron. As such, additional research geared toward the exploration of synaptic pathology biomarkers is crucial. This will not only enable their extensive clinical application, but also refine the optimization process of AD pharmacological trials.

Monitoring the interactions between alpha-synuclein and Tau in vitro and in vivo using bimolecular fluorescence complementation

Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates Its Oligomerization with Dopaminergic Phenotype in Mice

Α-Synuclein Modulates Tau Spreading in Mouse Brains

Multivalency drives interactions of alpha-synuclein fibrils with tau

Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization

Biophysical Studies of Amyloid-Binding Fluorophores to Tau AD Core Fibrils Formed without Cofactors

Quantitative detection of α-Synuclein and Tau oligomers and other aggregates by digital single particle counting

A Toxicogenic Interaction between Intracellular Amyloid-β and Apolipoprotein-E

Monitoring synaptic pathology in Alzheimer's disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives

Visualization of soluble tau oligomers in TauP301L-BiFC transgenic mice demonstrates the progression of tauopathy

Co-aggregation of α-synuclein with Amyloid-β Stabilizes β-sheet-rich Oligomers and Enhances the Formation of β-barrels

Bidirectional modulation of Alzheimer phenotype by alpha-synuclein in mice and primary neurons

Interaction Between A Beta And Tau In The Pathogenesis Of Alzheimer'S Disease

In vivo Validation of Bimolecular Fluorescence Complementation (BiFC) to Investigate Aggregate Formation in Amyotrophic Lateral Sclerosis (ALS)

Visualizing alpha-synuclein and iron deposition in M83 mouse model of Parkinson's disease in vivo

Associations between misfolded alpha‐synuclein aggregates and Alzheimer's disease pathology in vivo

In-vivo neuronal dysfunction by Aβ and tau overlaps with brain-wide inflammatory mechanisms in Alzheimer's disease

Synergy between amyloid-β and tau in Alzheimer’s disease

Relation between Alpha-Synuclein and Core CSF Biomarkers of Alzheimer’s Disease

Single Molecule Fluorescence Assay Of Alpha Synuclein Dimerization

Multiscale optical and optoacoustic imaging of amyloid-β deposits in mice